News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 650 results
December 2019
-
Media Release
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
EAST HANOVER, N.J., Dec. 11, 2019 /PRNewswire/ -- The submission is based on positive results from the Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with… -
Media Release
Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps
-
Media Release
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
- Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3- Fewer known CAR-T cell therapy… -
Media Release
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
November 2019
-
Media Release
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications(1)Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63… -
Media Release
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
-
Media Release
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
- PsO at Work provides a critical resource to help the more than 8 million Americans with psoriasis balance the demands of their jobs with managing their symptoms(1)- Lauper will highlight her PsO at… -
Media Release
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
October 2019
-
Media Release
Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
- STEP Program is available to US-based nonprofit patient advocacy organizations- Recipients will receive funding to support proposals that demonstrate innovation in awareness and education, self-… -
Media Release
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on BEOVU (brolucizumab-dbll) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of… -
Media Release
Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
Pagination
- ‹ Previous page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- …
- 55
- › Next page